Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: J Immunol. 2008 Jul 1;181(1):513–520. doi: 10.4049/jimmunol.181.1.513

FIGURE 5.

FIGURE 5

Treatment of PKC-θ−/− mice with a subtherapeutic dose of anti-CD154 mAb (mAb) or CTLA4-Ig prevented cardiac allograft rejection. a, Hearts from BALB/c donors were transplanted to WT mice treated with 0 mg (PKCθ+, n = 6), or once with 1 mg of anti-CD154 mAb (PKCθ+/1 × CD154 mAb, n = 6) or three times with 1 mg of anti-CD154 mAb (PKCθ+/3 × CD154 mAb, n = 8). Survival of the cardiac allografts was assessed over time. b, Hearts from BALB/c donors were transplanted to WT (n = 6) mice and PKC-θ−/− (n = 8) mice that were either not treated or treated once with 1 mg of anti- CD154 mAb (1× CD154 mAb). Survival of the cardiac allografts was assessed over time. c, Hearts from BALB/c donors were transplanted to WT (n = 5) mice and PKC-θ−/− (n = 6) mice that were treated with one dose of CTLA4-Ig (0.2 mg/mouse). Survival of the cardiac allografts was assessed over time.